Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals ...
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options
ADAP Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s ...